Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03148899 · ClinicalTrials.gov registry record · Phase 2
Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep
A Phase 2 study, sponsored by George Washington University.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT03148899 is a Phase 2 study that has completed, run by George Washington University. The registered enrollment target is 32 participants.
The verdict
NCT03148899, a Phase 2 study, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. OSA is a very prevalent disease with high cardiovascular risk factors, yet this disease remains very poorly treated. This proposal, based on the current literature and new basic science results detailed above on the role of oxytocin in cardiovascular control, will test if oxytocin administration improves adverse cardiovascular events during the recurrent nocturnal apneas in patients with OSA. This project will lay the groundwork and provide preliminary data to obtain NIH funding to test this important hypotheses more thoroughly and in larger clinical trials. This study will explore if intranasal oxytocin has any positive cardiovascular benefits in patients with sleep apnea.
Interventions
- DRUG Oxytocin Intranasal Spray
- DRUG Placebo Intranasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-07-27 |
| Est. Completion | 2020-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03148899
The ClinicalTrials.gov registry entry for NCT03148899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxytocin Intranasal Spray is the first listed.
NCT03148899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03148899 about?
NCT03148899 is a clinical study titled "Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep". In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. OSA is a very prevalent disease with high cardiovascular risk factors, yet this disease remains very poorly treated. This proposal, based on the current liter...
What is the current status of trial NCT03148899?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2016-07-27. Estimated completion is 2020-06-07.
What interventions are being tested in trial NCT03148899?
The interventions under investigation include: Oxytocin Intranasal Spray (DRUG), Placebo Intranasal Spray (DRUG).
Who is sponsoring clinical trial NCT03148899?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.